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Schistosomiasis is increasingly encountered among
travelers returning from the tropics; signs and symptoms of
travelers may differ from those of local populations. During
1993–2005, schistosomiasis was diagnosed in 137 Israeli
travelers, most of whom were infected while in sub-
Saharan Africa. Clinical findings compatible with acute
schistosomiasis were recorded for 75 (66.4%) patients and
included fever (71.3%), respiratory symptoms (42.9%), and
cutaneous symptoms (45.2%). At time of physical examina-
tion, 42 patients (37.1%) still had symptoms of acute schis-
tosomiasis, chronic schistosomiasis had developed in 23
(20.4%), and 48 (42.5%) were asymptomatic. Of patients
who were initially asymptomatic, chronic schistosomiasis
developed in 26%. Diagnosis was confirmed by serologic
testing for 87.6% of patients, but schistosome ova were
found in only 25.6%. We conclude that acute schistosomi-
asis is a major clinical problem among travelers, diagnostic
and therapeutic options for acute schistosomiasis are limit-
ed, and asymptomatic travelers returning from schistosomi-
asis-endemic areas should be screened and treated. 
S
chistosomiasis is a common parasitic infection in the
developing world, especially in Africa, where it is
hyperendemic in many regions. In Israel, schistosomiasis
is no longer endemic; however, cases have been reported
in travelers returning to Israel. Research on the clinical,
diagnostic, and therapeutic aspects of chronic infection in
disease-endemic populations is extensive; however, data
about schistosomiasis in travelers returning from these
areas are relatively sparse. Moreover, because local inhab-
itants of disease-endemic areas are exposed repeatedly, the
clinical manifestations may differ between residents and
visitors. We examined the epidemiology and clinical man-
ifestations of schistosomiasis in travelers returning to
Israel.
Methods
We used a list of all laboratory-confirmed diagnoses of
schistosomiasis in Israelis from the Ministry of Health in
Jerusalem, Israel, and the Centers for Disease Control and
Prevention (CDC) in Atlanta, Georgia, USA, during
1993–2005. Schistosomiasis is reportable in Israel, and all
diagnoses of schistosome ova in stool or urine in patients
should be referred to the central laboratory of the Ministry
of Health. Before August 2003, serologic tests were most-
ly referred to CDC for fast-ELISA screening with
Schistosoma mansoni adult microsomal antigen and for
confirmation and speciation by enzyme Western blot,
which has a sensitivity and specificity of ≈100% (1). Since
then, serologic diagnosis of schistosomiasis has become
available at the Ministry of Health and uses a soluble egg
antigen ELISA (IVD Research Inc., Carlsbad, CA, USA)
that is not species specific.
Clinical and epidemiologic data were available for all
cases diagnosed and patients treated at the Center for
Geographic and Tropical Medicine at Sheba Medical
Center. If data were incomplete, patients were contacted by
phone for additional details. We examined only cases in
Israeli travelers; cases in immigrants from disease-endem-
ic countries, who may have been previously exposed to
Schistosoma,  and foreign workers were excluded. The
study was approved by the ethical committee of Sheba
Medical Center.
Data were analyzed according to the presence of symp-
toms suggestive of acute schistosomiasis, the evolution to
chronic schistosomiasis (genital, urinary, or gastrointesti-
nal), or the diagnosis of asymptomatic schistosomiasis
through screening. A case of acute schistosomiasis was
defined as the onset of fever or hypersensitivity symp-
toms—urticarial rash, angioedema, dry cough or wheeze—
after exposure to infected water sources, with subsequent
confirmation by serologic or parasitologic testing. Asource
of infection was defined as self-reported exposure to fresh
water (e.g., bathing, diving) in a schistosomiasis-endemic
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Laboratories Ministry of Health, Jerusalem, Israel region. Exposure time was measured from the first day of
exposure to the last. The time from exposure to illness was
measured from the last exposure to the onset of symptoms.
The Fisher exact test and Student t test were used to ana-
lyze qualitative and quantitative variables, respectively;
level of significance was set at p<0.05.
Results
During 1993–2005, a total of 137 travelers returning to
Israel had a laboratory diagnosis of schistosomiasis. The
mean annual number of cases was 10.5 (range 1–13
cases/year) with the exception of 1998, when 27 cases
associated with rafting trips to the Omo River in Ethiopia
were diagnosed (2). The mean ± SD age of the travelers
was 27.1 ± 6.8 years, and the male:female ratio was 2.42:1.
S. haematobium caused 39.4% of cases; S. mansoni caused
29.9%, a mixed infection caused 16%, and undetermined
species (because the test was not species specific) caused
14.7%. One patient was seropositive for S. mekongi.
Epidemiologic data were available for 113 (82.5%)
patients. All infections were acquired in Africa except 1,
which was acquired by a traveler who had bathed in the
Mekong River in East Asia. Twenty-five (22.1%) patients
were exposed to 2 potentially infected water sources. The
other patients were exposed to only 1 source, mostly Lake
Malawi (57%) and the Omo River in Ethiopia (18%). The
median exposure time was 2 weeks (interquartile range
1.5–3.0 weeks).
Clinical data were available for 113 patients, of whom
104 were evaluated at the Sheba Medical Center (Table 1).
Of these, 48 (42.5%) were asymptomatic at the time of
evaluation, and the rest had symptoms of either acute or
chronic schistosomiasis (Figure); demographics and dura-
tion of travel were similar regardless of the symptom phase
at evaluation (Table 1). Immediate symptoms after bathing
(acute itching and rash, suggestive of swimmer’s itch)
were reported by only 8 (7.1%) patients.
Acute Schistosomiasis
Of the 42 (37.2%) patients with acute schistosomiasis,
symptoms occurred after a median of 3 weeks (mean ± SD
3.1 ± 2.7 weeks) from exposure. Fever was the prevalent
symptom, followed by respiratory symptoms and rash.
Only 4 (9.5%) patients had the complete complex of acute
schistosomiasis: fever, urticaria, and respiratory symp-
toms. An additional 33 patients reported having had an
episode of symptoms after exposure that was compatible
with acute schistosomiasis but resolved before medical
examination (Table 2). For most patients, the duration of
fever and urticaria was short, usually 1–2 weeks (range
1–6 weeks), and the median duration of respiratory symp-
toms was longer, 6 weeks (mean ± SD 15.4 ± 22.7 weeks).
Chronic Schistosomiasis
Of the 23 (20.3%) patients with chronic schistosomia-
sis, time from exposure to examination ranged from 4
months to 3 years (mean ± SD 58.0 ± 31.5 weeks). Among
them, 13 had a history of an acute schistosomiasis-like ill-
ness, 21 (91.3%) had genitourinary symptoms (17 hema-
turia or dysuria, 4 hematospermia), 2 had gastrointestinal
symptoms, and 1 had protracted fatigue and abdominal
pain. No patient had renal failure, obstructive uropathy,
cirrhosis, or central nervous system involvement; howev-
er, 7 (30.4%) patients underwent invasive diagnostic pro-
cedures for suspected tumors of the bladder or colon, and
their travel history was considered only after the diagnosis
of chronic schistosomiasis had been made.
Asymptomatic Schistosomiasis
A total of 48 (42.5%) patients were examined while
asymptomatic. These patients included 5 who were
referred because of eosinophilia and 5 who were hospital-
ized in Israel because of malaria and had serologic testing
because of their travel history. The rest of the patients
came in for screening because schistosomiasis had been
diagnosed in a traveling companion or because they had
been exposed to fresh water while traveling. A history of
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of these asymptomatic patients.
Laboratory Findings
For patients with acute schistosomiasis, physical exam-
ination findings were usually unremarkable. Laboratory
test results showed eosinophilia in 73% and mildly abnor-
mal liver function in 17%. Eosinophilia was more preva-
lent in patients with acute than with chronic
schistosomiasis (Table 1).
Diagnoses were confirmed by serologic testing for 120
(87.6%) patients. For only 35 (26.9%) patients, mostly
those with chronic schistosomiasis, were schistosome ova
found in urine, semen, or stool samples (Table 1). For 6
patients, the diagnosis was established by chance in a tis-
sue biopsy; subsequent testing showed ova in the stool or
urine of 5 of these 6 patients. A diagnosis of schistosomia-
sis was made for 1 additional patient, whose colectomy
specimen (colectomy performed because of familial ade-
nomatous polyposis) contained schistosome ova 10 years
after exposure (3).
Treatment 
Praziquantel was offered to all 113 patients, but follow-
up information after treatment was available for only 65.
Eosinophil counts declined from a mean ± SD of 2,100 ×
109/L ± 1,850 to 970 × 109/L ± 1,575 (p<0.01). Because
respiratory symptoms were the least self-limiting form of
acute schistosomiasis, response to therapy was evaluated
in these patients. Among the 38 patients with respiratory
symptoms, 4 cases resolved before praziquantel therapy,
and follow up was incomplete in 12. Of the remaining 22
patients, in 9 cases there was an acute exacerbation of
symptoms after praziquantel therapy, lasting from a few
days to 3 weeks. Corticosteroids were prescribed for 5
patients with protracted respiratory symptoms, and repeat-
ed courses of praziquantel were prescribed for 6. Overall,
in 20 of 22 cases, symptoms improved within 2 months
after therapy. A history of asthma was not associated with
a worsening of symptoms after therapy.
Discussion
Although schistosomiasis is widespread throughout
much of the tropics, we found that among Israeli travelers,
schistosomiasis is acquired almost exclusively in Africa.
This finding supports data from the GeoSentinel group and
the TropNetEurope surveillance network, which report that
Africa was the source for ≈90% of all cases (4,5). The
absence of cases from other disease-endemic regions may
be because schistosomiasis is often a focal disease, and
perhaps infections are not commonly found in the specific
locations frequented by travelers in South America and the
Far East.
The schistosome life cycle has 3 phases in the human
host, and all have their clinical counterparts. The first
phase is host penetration by cercaria, which is usually
manifested as a transient (hours) itchy eruption that occurs
soon after exposure and is known as swimmer’s itch or
cercarial dermatitis. The second phase is schistosomulae
tissue migration and maturation and is associated with
transient (days to weeks) hypersensitivity, which gives rise
to the syndrome of acute schistosomiasis. The third phase,
endovascular egg production, is protracted (years) and is
associated with organ damage (genitourinary, gastroin-
testinal, or ectopic migration to other organs).
In our cohort, a history suggestive of the first phase,
swimmer’s itch, was infrequent, found in 7.1% of patients.
Other case series also suggest that it occurs in only
12%–36% of patients with schistosomiasis (6–8). For many
of our patients, data were collected long after exposure, so
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Figure. Progression of schistosomiasis symptoms among Israeli
travelers (n = 113), 1993–2005. they may have forgotten such a transient phenomenon.
Obviously, the absence of a history of swimmer’s itch can-
not be used to exclude schistosomiasis. 
Our data show acute schistosomiasis, the second phase,
to be the predominant form of the disease in travelers,
noted by 66.4%. Travelers in that respect are markedly dif-
ferent from local populations and immigrants, among
whom acute schistosomiasis is rare. Some textbooks sug-
gest that acute schistosomiasis is a syndrome that typical-
ly results from heavy infestations with S. japonicum or S.
mansoni and rarely, if ever, from S. haematobium (9). Our
findings suggest that, to the contrary, acute schistosomia-
sis occurs with S. haematobium and with S. mansoni. We
believe that acute schistosomiasis is an immune phenome-
non, is not species specific, and can develop after infection
with each of the schistosomae that infect humans. That
some species (e.g., S. mekongi and S. interacalatum) are
rarely reported in the literature as causing acute schistoso-
miasis may merely reflect lack of traveler exposure.
The acute symptom complex that appears several
weeks after exposure is often called Katayama fever, hav-
ing been described in Katayama district near Hiroshima in
Japan in 1847 (10). However, our data show that fever
occurs in only 71% of patients with acute schistosomiasis;
similarly, data from the early 20th century show that fever
was not universally present during the acute toxemic phase
(11). We therefore believe that acute schistosomiasis,
rather than Katayama fever, should be the preferred name
for this syndrome.
Although fever is indeed not universal with acute schis-
tosomiasis, when it does occur, it is usually high; therefore,
malaria is a major differential diagnosis. This may help
explain why most patients evaluated abroad were treated
for malaria. Antimalarial drugs were offered to some
patients despite negative smear results. In other patients
reported to have positive malaria smear results in Africa,
serologic testing for plasmodia after their return was found
to be negative, which adds to reports of the unreliability of
tests performed in Africa (12). For other patients, fever and
urticarial rash were diagnosed as allergic reactions and
treated with glucocorticoids. Urticarial rash or eosinophil-
ia are clinical clues that may help differentiate between the
fever of acute schistosomiasis and that of malaria. Also,
persistent fever despite documented parasitologic response
in cases of proven malaria should alert the clinician to the
possibility of coinfection.
The 3 major clinical features—fever, skin, and respira-
tory symptoms—occur in combination in only a small per-
centage of patients with acute schistosomiasis (Table 2).
Even then, they often do not appear simultaneously.
Unfortunately, in our experience, even when returning trav-
elers had a history of the complete symptom complex, the
clinical diagnosis was frequently missed. The respiratory
symptoms tend to follow a more protracted course, and
unless a thorough history is taken, the case may be misdi-
agnosed as allergy or asthma.
In chronic schistosomiasis, the third phase, genitouri-
nary problems and, less often, gastrointestinal problems
occur. Late sequelae such as cirrhosis, portal/pulmonary
hypertension, or obstructive uropathy are the aftermath of
heavy or repeated infection typical for local populations;
absence of these sequelae among travelers is not surpris-
ing. Of seropositive patients who were initially asympto-
matic, chronic schistosomiasis developed in 26% (Figure).
The question of whether asymptomatic travelers with his-
tory of freshwater exposure should be screened and treat-
ed for schistosomiasis is clearly pertinent (2). Our data
strongly support the recommendation to screen and treat.
Our study illustrates the problems encountered in diag-
nosing Schistosoma infection in patients evaluated during
acute schistosomiasis. Stool and urine examinations for
ova were largely negative, diagnoses relied on serologic
testing, and therefore most diagnoses were made post
facto. Although serologic testing appears to be very sensi-
tive, a caveat must be added that most serum samples were
collected relatively late in the course of acute schistosomi-
asis. For the acutely ill febrile returning traveler, serologic
test results may be negative, as occurred for 2 of our
patients for whom an additional specimen was required for
diagnosis. 
The ability to diagnose chronic schistosomiasis by ova
detection was higher (Table 1); however, for many
patients, only serologic testing gave a positive result. Thus,
ova detection, which is the main diagnostic tool in schisto-
somiasis-endemic countries, often gives negative results
for travelers. Negative results occur during the acute stage
because symptoms start before oviposition and during the
chronic stage because of low-level or intermittent oviposi-
tion. Successful ova detection entails multiple examina-
tions of stool or urine; sensitivity depends greatly on
technique and expertise, which may be declining at many
Western institutions.
Treatment of schistosomiasis can also be problematic.
Praziquantel is considered the drug of choice for schistoso-
miasis but possesses little activity against the juvenile forms
of the helminth (schistosomulae) (13). Of our patients who
were exposed in Lake Malawi, 11 took praziquantel soon
after exposure while abroad, as a form of preemptive thera-
py for later schistosomiasis, which is a common recommen-
dation for visitors to Lake Malawi. Of these, acute
schistosomiasis developed in 7, symptoms lasted 5–45
weeks, and chronic schistosomiasis developed in 2. These
cases show that praziquantel given shortly after exposure
does not preclude later clinical infection.
The limitations of praziquantel for treating acute schis-
tosomiasis were clearly seen in our patients. For those who
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and the contribution of therapy is unclear. For patients with
respiratory symptoms, therapy was sometimes associated
with an acute exacerbation of symptoms. For some
patients, cough and dyspnea continued for many months
after treatment. Our policy is to repeat praziquantel treat-
ment after 3 months, which may be why we did not see
chronic schistosomiasis in this group.
Conclusions
Most cases of schistosomiasis in Israeli travelers are
acquired in sub-Saharan Africa. For travelers, most symp-
tomatic cases of schistosomiasis are acute, diagnosis by
ova detection is usually negative, and serologic testing,
when performed too early, may give false-negative results.
Modern practitioners may not be in a better situation than
those who treated acute schistosomiasis cases in the 1920s
(11). Our findings lend support for screening asympto-
matic travelers to schistosomiasis-endemic areas because
chronic schistosomiasis will develop in many of them.
Better knowledge of the various possible manifestations of
schistosomiasis should decrease the time to diagnosis of
acute and chronic schistosomiasis. Physicians should
promptly evaluate returning travelers for schistosomiasis
even if they do not report the complete symptom complex.
However, in the absence of effective treatment for acute
schistosomiasis, new diagnostic methods and new drugs
that affect the parasite at an early stage are needed.
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